A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting

Anesthesia and Analgesia

Volumn 104, Issue 5, 2007, Pages 1082-1089

  Gan, Tong J ^a   Apfel, Christian C ^b   Kovac, Anthony ^c   Philip, Beverly K ^d   Singla, Neil ^e   Minkowitz, Harold ^f   Habib, Ashraf S ^a   Knighton, Jennifer ^g   Carides, Alexandra D ^g   Zhang, Hong ^g   Horgan, Kevin J ^g   Evans, Judith K ^g   Lawson, Francasca C ^g   Ahadian, Farshad ^h   Andres, David ^h   Blood, J Todd S ^h   Candiotti, Keith Allen ^h   Chelly, Jacques E ^h   Cook, Paul ^h   D'Angelo, Robert ^h   Edmondson, Donald ^h   Fleisher, Lee A ^h   Tong, Joo Gan ^h   Gebhard, Ralf ^h   Gingrich, Kevin ^h   Grass, Jeffrey A ^h   Groudine, Scott ^h   Hatridge, John ^h   Houden, Timothy ^h   Howie, Michael B ^h   Janicki, Piotr K ^h   Katz, Daniel ^h   Kaul, Bupesh ^h   Knapp, Robert ^h   Kovac Jr , Anthony L ^h   Lauer, Kathryn K ^h   Lichtor, J Lance ^h   Melson, Timothy ^h   Myers, Kelly ^h   Norman, Peter H ^h   Pearman, Michael H ^h   Philip, James ^h   Singla, Neil K ^h   Tark, Marvin ^h   White, Paul F ^h   Witkowski, Thomas A ^h   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HUNTINGTON MEMORIAL HOSPITAL   (United States)

^f MEMORIAL HERMANN HOSPITAL   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON;

ABDOMINAL SURGERY; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; ONDANSETRON; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, NEUROKININ-1;

EID: 34247504043     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000263277.35140.a3     Document Type: Article

References (26)

1. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology 1992;77:162-84.
2. Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994;78:7-16.
3. Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology 1999;91:693-700.
4. Gan TJ, Ginsberg B, Grant AP, Glass PS. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. Anesthesiology 1996;85:1036-42.
5. Apfel CC, Korttila K, Abdalla M, et al; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441-51.
6. Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985;7:191-211.
7. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-6.
8. Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Drugs 1997;53:206-34.
9. Amin AH, Crawford TBB, Gaddum JH. The distribution of substance P and 5-hydroxy-tryptamine in the central nervous system of the dog. J Physiol 1954;126:596-618.
10. Gonsalves S, Watson J, Ashton C. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 1996;305:181-5.
11. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35:1121-9.
12. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99994. Neuropharmacology 1994;33:259-60.
13. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000;39:652-63.
14. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80.
15. Gesztesi Z, Scuderi PE, White PF, et al. Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000;93:931-7.
16. Diemunsch P, Schoeffler P, Bryssine B, et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999;82:274-6.
17. EMEND® capsules (Merck) (aprepitant). USA [package insert]. 2006.
18. Gralla RJ, Roila F, Tonato M. The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer 2005;13:77-9.
19. Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth Analg 1970;49:924-34.
20. Boogaerts JG, Vanacker E, Seidel L, et al. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand 2000;44:470-4.
21. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26.
22. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.
23. de Wit R, Hesketh PJ, Warr D, et al. The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy: a review. Am J Cancer 2005;4:35-48.
24. Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998;86:274-82.
25. Apfel C, Paura A, Jokela R, et al. Ondansetron comparably reduces the relative risk of nausea and vomiting. Anesth Analg 2005;S4:100.
26. Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 2000;92:958-67.